During the past decade, Revmatologicka ambulance conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Revmatologicka ambulance" are "Rheumatoid Arthritis" (2 trials). Many other conditions were trialed in "Revmatologicka ambulance" in a lesser frequency.

Most popular intervention types in "Revmatologicka ambulance" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Apremilast 20 mg" (1 trials), "Apremilast 30 mg" (1 trials), "PF-06650833" (1 trials) and "Tofacitinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Revmatologicka ambulance" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Revmatologicka ambulance". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Revmatologicka ambulance, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Revmatologicka ambulance, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".